Nigeria’s health minister announced the launch of a new malaria vaccine on Thursday, which would be given to recipients at no cost. This represents a major advancement in the country’s fight against the fatal illness.
With the launch, the nation became one of the first globally to support the novel R21 vaccine, which was created by Oxford University scientists and produced by Novavax and the Serum Institute of India.
In April of last year, Nigeria’s drugs regulator gave the vaccine provisional approval.
According to Nigeria’s Health Minister Muhammad Ali Pate, 846,200 doses of the vaccine have been distributed, obtained through collaboration with UNICEF, the Vaccine Alliance, and the international vaccine consortium Gavi. On October 26, 153,800 more doses are needed to reach the million mark.
“The Vaccines are not enough, so in the context that they are not enough but free, I want to encourage all well-meaning Nigerians to take advantage of the limited availability and make their wards available to be administered and protected,” Pate told reporters at the launch in the capital Abuja.
Before going nationwide, Pate stated that the implementation would begin with two pilot states: Kebbi in the north and Bayelsa on the coast.
Every year, malaria—a disease carried by mosquitoes—kills over 600,000 individuals, the majority of whom are infants and young children from Africa.
According to a 2023 World Health Organisation (WHO) study, Nigeria, the most populous country in Africa, is the world’s worst-affected country, accounting for 31% of all malaria-related deaths worldwide.